Buy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oquezna

6d ago, source:

Analyst Joseph Stringer of Needham maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), retaining the price ...

Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst

on MSN ago, source:

Rhythm Pharmaceuticals (NASDAQ:RYTM), and Vaxcyte (NASDAQ:PCVX) are the most likely takeout targets in the pharma space, ...

Needham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)

3d ago, source:

In a report released today, Joseph Stringer from Needham maintained a Hold rating on Lexicon Pharmaceuticals (LXRX – Research Report).

12 Most Shorted Stocks in 2024

6d ago, source:

In this article, we will take a detailed look at the 12 Most Shorted Stocks in 2024. For a quick overview of such stocks, ...

PTC Therapeutics: Q1 Earnings Snapshot

15h ago, source:

SOUTH PLAINFIELD, N.J. (AP) — SOUTH PLAINFIELD, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Thursday reported a loss of $91.6 million in its first quarter. The South Plainfield, New Jersey-based ...

Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time

12d ago, source: Seeking Alpha

The combined company will operate under the name “Gyre Therapeutics, Inc.” (“Gyre”). As a result of the business combination, ...

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

1d ago, source: TMCnet

HB-200 in combination with pembrolizumab pivotal Phase 2/3 trial design summary The trial will treat patients with HPV16+ recurrent/metastatic PD-L1 CPS = 20 oropharyngeal squamous cell carcinoma in ...